STENTYS announced earnings results for the six months ended June 30, 2018. For the period, the company reported revenue was €3,639,000 against €3,548,000 a year ago. Total income was €3,642,000 against €3,548,000 a year ago. Recurring operating loss was €2,898,000 against €2,816,000 a year ago. Operating loss was €3,010,000 against €2,817,000 a year ago. Net loss was €3,138,000 against €2,922,000 a year ago. The sales performances of the new group were affected by the integration process that required the adaptation of teams and partners to this new organization. The gradual harmonization of sales offer is progressing as planned, and will enable the Group due to its diversity and complementarity to cope with the context of a stent market that has become competitive.